Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:accessories |
long-term supply agreements with clients
works with trusted supply chain partners |
| gptkbp:acquisition |
Samsung Biologics acquired a facility from Biogen
|
| gptkbp:awards |
recognized for excellence in manufacturing
|
| gptkbp:ceo |
John Rim
|
| gptkbp:certification |
ISO certified
|
| gptkbp:clinical_trial |
conducts clinical trials for clients
provides clinical trial support services supports clinical development programs |
| gptkbp:collaborations |
engages in research collaborations
develops global partnerships for growth with global biotech firms |
| gptkbp:community_engagement |
active in local community initiatives
|
| gptkbp:customer_base |
diverse customer base
|
| gptkbp:educational_programs |
robust quality assurance processes
|
| gptkbp:employees |
over 2,000
|
| gptkbp:feedback |
committed to customer satisfaction.
|
| gptkbp:financial_performance |
strong financial performance
|
| gptkbp:focus |
monoclonal antibodies
biosimilars cell and gene therapies |
| gptkbp:founded |
gptkb:2011
|
| gptkbp:has_expansion |
new manufacturing facilities planned
|
| gptkbp:headquarters |
gptkb:Incheon,_South_Korea
|
| https://www.w3.org/2000/01/rdf-schema#label |
Samsung Bio Logics
|
| gptkbp:industry |
gptkb:Company
expertise in biomanufacturing processes |
| gptkbp:innovation |
drives innovation in biopharmaceuticals
|
| gptkbp:investment |
invests in advanced technologies
|
| gptkbp:location |
gptkb:Songdo_International_Business_District
|
| gptkbp:market |
global market presence
|
| gptkbp:marketing_strategy |
aggressive market strategy
|
| gptkbp:mission |
to provide high-quality biopharmaceuticals
|
| gptkbp:parent_company |
gptkb:Samsung_Group
|
| gptkbp:partnership |
various pharmaceutical companies
collaborates with academic institutions strategic partnerships with leading firms |
| gptkbp:population_trend |
monitors market trends closely
|
| gptkbp:produced_by |
up to 362,000 liters
uses single-use technology |
| gptkbp:production_company |
diverse product portfolio
|
| gptkbp:products |
focus on product development and innovation
|
| gptkbp:reach |
operates in multiple countries
|
| gptkbp:regulatory_compliance |
FDA approved
EMA approved ensures regulatory compliance in all operations |
| gptkbp:research_and_development |
significant investment in research and development
|
| gptkbp:revenue |
over $1 billion
|
| gptkbp:safety_features |
adheres to high safety standards
|
| gptkbp:services |
quality control
contract manufacturing biologics development |
| gptkbp:strategic_importance |
focus on innovation and quality
|
| gptkbp:supply_chain |
robust supply chain management
provides clinical supply services |
| gptkbp:sustainability_initiatives |
environmental responsibility programs
|
| gptkbp:technology |
facilitates technology transfer for clients
state-of-the-art biomanufacturing technology |
| gptkbp:vision |
to be a global leader in biopharmaceutical manufacturing
|
| gptkbp:website |
www.samsungbiologics.com
|
| gptkbp:bfsParent |
gptkb:Biogen
|
| gptkbp:bfsLayer |
4
|